Arix Bioscience and Ipsen sign a strategic agreement to develop and commercialise innovative therapies

21st February 2018

LONDON, PARIS 21 FEBRUARY 2018:

Arix Bioscience plc (LSE:ARIX) (“Arix”), a global healthcare and life science company supporting medical innovation, and Ipsen (Euronext: IPN; ADR:IPSEY), a global specialty-driven biopharmaceutical company focused on innovation and specialty care, today announced a strategic agreement to develop and commercialise innovative therapies.

Arix will provide Ipsen with access to its unique network of professional and scientific advisors, and the chance to invest in opportunities in Arix’s new and existing businesses. In return, Ipsen will contribute research, development and commercial expertise to the partnership. Arix and Ipsen will collaborate to identify opportunities and jointly create new companies focused primarily on the development and commercialisation of innovative therapies for patients.

Joe Anderson, Chief Executive Officer of Arix Bioscience plc, commented:“This agreement brings together Ipsen’s deep expertise in drug development and commercialization with Arix’s proven capacity to identify new opportunities and build companies to develop innovative new therapies in areas of high unmet medical need. Arix is committed to acquiring interests in, and assisting in the development of, businesses that bring medical innovation and address important areas with limited available treatment options. We look forward to collaborating with Ipsen to identify new opportunities to drive innovation, improve patient outcomes and, ultimately, future value for our shareholders.”

“We are committed to discovering and developing innovative therapeutic solutions for targeted debilitating diseases and improving the quality of life for patients. By building this relationship with Arix, we can benefit from Arix’s leading networks, advisors and businesses and can support these in turn with our R&D and commercialisation capabilities and expertise. We look forward to working together and supporting the next generation of companies developing life-changing medicines for patients.”

David Meek, Chief Executive Officer of Ipsen

Arix made investments into 13 innovative life science companies in 2016 and 2017, with multiple value-creating milestones expected over the next 18 months. Arix expects to continue to build on its already rich pipeline to provide funding and expertise to additional new businesses in 2018.

Ends